1. Home
  2. MESO vs NVGS Comparison

MESO vs NVGS Comparison

Compare MESO & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • NVGS
  • Stock Information
  • Founded
  • MESO 2004
  • NVGS 1997
  • Country
  • MESO Australia
  • NVGS United Kingdom
  • Employees
  • MESO N/A
  • NVGS N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • NVGS Marine Transportation
  • Sector
  • MESO Health Care
  • NVGS Consumer Discretionary
  • Exchange
  • MESO Nasdaq
  • NVGS Nasdaq
  • Market Cap
  • MESO 1.3B
  • NVGS 1.1B
  • IPO Year
  • MESO N/A
  • NVGS N/A
  • Fundamental
  • Price
  • MESO $18.18
  • NVGS $14.53
  • Analyst Decision
  • MESO Buy
  • NVGS Strong Buy
  • Analyst Count
  • MESO 2
  • NVGS 3
  • Target Price
  • MESO $24.00
  • NVGS $22.33
  • AVG Volume (30 Days)
  • MESO 319.1K
  • NVGS 279.6K
  • Earning Date
  • MESO 08-28-2025
  • NVGS 11-05-2025
  • Dividend Yield
  • MESO N/A
  • NVGS 1.39%
  • EPS Growth
  • MESO N/A
  • NVGS 12.51
  • EPS
  • MESO N/A
  • NVGS 1.26
  • Revenue
  • MESO $17,198,000.00
  • NVGS $566,889,000.00
  • Revenue This Year
  • MESO $288.50
  • NVGS $3.68
  • Revenue Next Year
  • MESO $167.17
  • NVGS N/A
  • P/E Ratio
  • MESO N/A
  • NVGS $11.44
  • Revenue Growth
  • MESO 191.39
  • NVGS 1.19
  • 52 Week Low
  • MESO $7.09
  • NVGS $10.55
  • 52 Week High
  • MESO $22.00
  • NVGS $17.53
  • Technical
  • Relative Strength Index (RSI)
  • MESO 58.45
  • NVGS 29.41
  • Support Level
  • MESO $17.10
  • NVGS $15.16
  • Resistance Level
  • MESO $20.18
  • NVGS $15.77
  • Average True Range (ATR)
  • MESO 0.56
  • NVGS 0.36
  • MACD
  • MESO 0.17
  • NVGS -0.17
  • Stochastic Oscillator
  • MESO 55.52
  • NVGS 6.52

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About NVGS Navigator Holdings Ltd. (Marshall Islands)

Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.

Share on Social Networks: